We are live on ! Find out more
IHE icon

iShares US Pharmaceuticals ETF

87 hedge funds and large institutions have $259M invested in iShares US Pharmaceuticals ETF in 2014 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 36 increasing their positions, 25 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

44% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 25

13% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 8

6% more capital invested

Capital invested by funds: $244M → $259M (+$14.7M)

1% more funds holding

Funds holding: 8687 (+1)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

1.73% less ownership

Funds ownership: 111.31%109.58% (-1.7%)

Holders
87
Holders Change
+1
Holders Change %
+1.16%
% of All Funds
2.5%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.06%
New
9
Increased
36
Reduced
25
Closed
8
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
HSBC Holdings
51
HSBC Holdings
United Kingdom
$459K -$400K -9,300 -48%
WA
52
WFG Advisors
Texas
$453K
JP Morgan Chase
53
JP Morgan Chase
New York
$403K -$226K -5,262 -37%
LTFS
54
Ladenburg Thalmann Financial Services
Florida
$388K +$28K +651 +8%
Deutsche Bank
55
Deutsche Bank
Germany
$386K +$7.87K +183 +2%
GA
56
Gateway Advisory
New Jersey
$361K
William Blair & Company
57
William Blair & Company
Illinois
$351K
CIBC World Market
58
CIBC World Market
Ontario, Canada
$339K +$87K +2,022 +37%
CCM
59
Condor Capital Management
New Jersey
$305K +$292K +6,783 New
CWM
60
Concert Wealth Management
California
$296K -$15K -348 -5%
Ameriprise
61
Ameriprise
Minnesota
$294K -$67.1K -1,560 -19%
BFS
62
Bradley Foster & Sargent
Connecticut
$287K -$12.9K -300 -4%
DC
63
Davenport & Co
Virginia
$269K +$6.45K +150 +3%
SI
64
Stephens Inc
Arkansas
$243K -$1.94K -45 -0.8%
EFS
65
Essex Financial Services
Connecticut
$238K
AFG
66
Arkansas Financial Group
Arkansas
$230K -$17.3K -402 -7%
Cambridge Investment Research Advisors
67
Cambridge Investment Research Advisors
Iowa
$230K +$220K +5,109 New
JMPWA
68
JP Morgan Private Wealth Advisors
California
$228K +$218K +5,070 New
BHB
69
Bank Hapoalim BM
Israel
$209K
EWM
70
Edge Wealth Management
New York
$208K
Creative Planning
71
Creative Planning
Kansas
$208K +$89.2K +2,073 +81%
B
72
Baird
Wisconsin
$200K +$191K +4,443 New
Envestnet Asset Management
73
Envestnet Asset Management
Illinois
$156K +$26.3K +612 +21%
BRWA
74
B. Riley Wealth Advisors
Florida
$150K +$143K +3,330 New
MFS
75
MSI Financial Services
Massachusetts
$119K +$22.8K +531 +25%

IHE Hedge Fund Activity: Q2 2014 in Review

87 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q2 2014, worth a combined $259M — up 6% from $244M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new IHE positions and 8 closed out — a net gain of 1 holder — while 36 added to existing stakes and 25 trimmed.

The largest buyer was Bank of America, adding an estimated $6.2M. The largest seller was Clark Capital Management Group, exiting entirely with an estimated $7.92M sold.

  • 87 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q2 2014, up from 86 in Q1 2014.
  • Funds reported $259M of iShares US Pharmaceuticals ETF stock for Q2 2014, up 6% quarter-over-quarter.
  • 9 funds opened new iShares US Pharmaceuticals ETF positions in Q2 2014 and 8 closed out, a net change of +1 holder.
  • The largest iShares US Pharmaceuticals ETF buyer in Q2 2014 was Bank of America, an estimated $6.2M added.
  • The largest iShares US Pharmaceuticals ETF seller in Q2 2014 was Clark Capital Management Group, an estimated $7.92M sold.

Based on aggregated 13F filings for Q2 2014.